Memphis Pharmaceuticals & Chemical Industries (EGX: MPCI)

MPCI Cash Flow Statement

Financials in millions EGP. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	191.46	191.46	90.44	74.09	41.81	17.41
Depreciation & Amortization	12.18	12.18	-	-	-	9.68
Other Operating Activities	-20.43	-20.43	-32.5	-37.62	-38.33	-30.27
Operating Cash Flow	183.21	183.21	57.94	36.47	3.47	-3.18
Operating Cash Flow Growth	216.20%	216.20%	58.88%	950.33%	-	-
Capital Expenditures	-24.37	-24.37	-11.45	-12.92	-2.07	-0.8
Other Investing Activities	54.97	54.97	10.87	7.69	4.68	2.53
Investing Cash Flow	30.59	30.59	-0.58	-5.24	2.62	1.73
Long-Term Debt Issued	174.7	174.7	2.34	-	-	-
Net Debt Issued (Repaid)	174.7	174.7	2.34	-	-	-
Common Dividends Paid	-12.17	-12.17	-	-	-0.25	-
Financing Cash Flow	162.53	162.53	2.34	-	-0.25	-
Miscellaneous Cash Flow Adjustments	-0	-0	-	-	-	-0
Net Cash Flow	376.33	376.33	59.7	31.23	5.84	-1.45
Free Cash Flow	158.83	158.83	46.49	23.55	1.4	-3.98
Free Cash Flow Growth	241.66%	241.66%	97.45%	1578.00%	-	-
Free Cash Flow Margin	18.22%	18.22%	7.00%	4.27%	0.27%	-0.82%
Free Cash Flow Per Share	28.24	28.24	8.26	4.19	-	-0.71
Cash Interest Paid	14.26	14.26	36.79	-	-	0
Cash Income Tax Paid	24.84	24.84	22.41	7.04	9.38	7.01
Levered Free Cash Flow	279.99	279.99	36.76	-5.31	-1.42	33.2
Unlevered Free Cash Flow	288.9	288.9	36.76	-5.31	-1.42	33.2
Change in Net Working Capital	-185.17	-185.17	11.72	35.54	20.69	-17.06

Source: S&P Capital IQ. Standard template. Financial Sources.